AC IMMUNE SA SF-02 Total Liabilities
AC IMMUNE SA SF-02 total liabilities. Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) has total liabilities worth €115.23 Million EUR (≈ $134.72 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of AC IMMUNE SA SF-02 to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AC IMMUNE SA SF-02 (2021–2025)
Total liabilities of AC IMMUNE SA SF-02 from 2021 to 2025. This chart illustrates how AC IMMUNE SA SF-02's total liabilities have evolved over time, based on quarterly financial data. Explore IMR long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
AC IMMUNE SA SF-02 Competitors by Total Liabilities
The table below lists competitors of AC IMMUNE SA SF-02 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arizon RFID Tech (Cayman) Co
TW:6863
|
Taiwan | NT$2.81 Billion |
|
Kepler Weber S.A
SA:KEPL3
|
Brazil | R$825.13 Million |
|
Evommune, Inc.
NYSE:EVMN
|
USA | $24.36 Million |
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
China | CN¥1.07 Billion |
|
Taaleri Oyj
HE:TAALA
|
Finland | €84.96 Million |
|
104 Corporation
TW:3130
|
Taiwan | NT$2.79 Billion |
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
USA | $77.34 Million |
|
Squirrel Media SA
MC:SQRL
|
Spain | €163.52 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down AC IMMUNE SA SF-02's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMR asset base.
Liquidity & Leverage Metrics
AC IMMUNE SA SF-02 Total Liabilities Ratios Explained
AC IMMUNE SA SF-02 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AC IMMUNE SA SF-02's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual total liabilities of AC IMMUNE SA SF-02 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €109.37 Million ≈ $127.86 Million |
-7.82% |
| 2024-12-31 | €118.64 Million ≈ $138.71 Million |
+435.13% |
| 2023-12-31 | €22.17 Million ≈ $25.92 Million |
+30.83% |
| 2022-12-31 | €16.95 Million ≈ $19.81 Million |
-42.48% |
| 2021-12-31 | €29.46 Million ≈ $34.45 Million |
-- |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more